Stay informed with the latest biotech and pharma industry news and insights by signing up for BioPharma Dive. Explore all our free newsletter options here: https://lnkd.in/ggT43zrR
BioPharma Dive
Online Audio and Video Media
Washington, District of Columbia 14,484 followers
We provide business journalism and in-depth insight into the most impactful news and trends shaping biotech and pharma
About us
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 13 million decision-makers in the most competitive industries.
- Website
-
http://www.biopharmadive.com
External link for BioPharma Dive
- Industry
- Online Audio and Video Media
- Company size
- 201-500 employees
- Headquarters
- Washington, District of Columbia
Updates
-
The company plans to start a late-stage study next year, after a smaller trial found its drug offered “robust and consistent” benefits on communication, cognition and motor function.
Ionis plots next steps for Angelman drug Biogen passed on
biopharmadive.com
-
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
Private biotech M&A surges amid difficult IPO market
biopharmadive.com
-
At least 11 health systems were experiencing issues Friday after an update by cybersecurity firm CrowdStrike went awry.
Global tech outage hits US hospitals
biopharmadive.com
-
The offering comes days after the publication of a paper showing what analysts said was early proof that “off-the-shelf” cell therapies can treat inflammatory diseases.
Artiva prices $167M IPO, riding optimism for autoimmune cell therapy
biopharmadive.com
-
Jefferies analyst Andrew Tsai views growing sales for J&J’s depression treatment as evidence that psychedelics like it can be commercially viable.
In strengthening Spravato sales, a positive sign for psychedelic drugs
biopharmadive.com
-
The German drugmaker will offer a 92% discount on a copycat version of Humira for people who pay cash for the drug through GoodRx.
Boehringer cuts price of Humira biosimilar in bid to build use
biopharmadive.com
-
Treatment led to "clinically meaningful" weight loss over four weeks, but longer studies will be needed to compare it to Wegovy and Zepbound.
Obesity pill from Roche shows promising weight loss in small study
biopharmadive.com
-
Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.
Gilead’s CMO to depart next year
biopharmadive.com
-
In the suit, Vertex argues HHS’ stance forces a “Hobson’s choice” on people with sickle cell seeking to undergo the potentially curative treatment.
Vertex sues US over limits on providing fertility services to Casgevy patients
biopharmadive.com